Cellectis SA
(XPAR:ALCLS)
€
1.48
-0.02 (-1.33%)
Market Cap: 148.14 Mil
Enterprise Value: -14.65 Mil
PE Ratio: 0
PB Ratio: 1.29
GF Score: 44/100 Cellectis SA at Citi Biotech Conference Transcript
Sep 04, 2019 / 05:30PM GMT
Release Date Price:
€10.93
(+3.11%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
The next panel is cell therapy, up-and-comers in the cell therapy space. So it's my pleasure to introduce our 3 distinguished guests, from Atara the CEO, Pascal Touchon; and from Cellectis, André Choulika; and, of course, from Fate, in the middle, Scott Wolchko. So welcome all of you. Thanks for making the time.
Questions & Answers
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
I guess the question I have to start out the session is at a 30,000-foot level, could each of you give your thoughts on what are the ingredients to create a successful cell therapy? What are the things you want to do? And what are the things that you absolutely want to avoid on the path to a product that's a cell-based therapy? So you want to kick it off, Pascal?
Pascal Touchon;Yigal Dov Nochomovitz<
Atara Biotherapeutics, Inc. - President, CEO & Director
Yes, with pleasure. I mean thank you for inviting me, by the way.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot